Author: techtcell@gmail.com

Tcelltech CAR-T Cell IND Approved for Brain Tumor Treatment

On January 22, 2024, Tcelltech’s “TX103 CAR-T cell” was approved by the National Center for Drug Evaluation (CDE) IND for the treatment of malignant glioma. TX103 is an original CAR-T cell therapy drug targeting B7-H3 (CD276). The drug received FDA clinical trial approval in September 2023; It has also been granted orphan drug designation by […]

Tcelltech CAR-T Cells Approved by FDA

On September 30, 2023, TX103 CAR-T cell IND from Tcelltech Tiantan Biotech Co., Ltd. and its US Tcelltech company received tacit approval from the US Food and Drug Administration (FDA) for the treatment of malignant glioblastoma. TX103, a B7-H3 targeted CAR-T cell drug, has shown excellent safety and efficacy signals in early clinical trials for […]

Tcelltech CAR-T Cell Therapy Recognized by FDA Orphan Drug (ODD)

On June 21, 2023, Tcelltech Biotech’s B7-H3 targeted CAR-T cell therapy product, It has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) Office of Orphan Drug Development for the treatment of malignant glioblastoma. According to the FDA Orphan Drug Act, orphan drug status will enjoy several preferential policies, including […]

Gangxiong Huang, MD

Co-founder, CEO

Dr. Huang’s research has focused on tumor metastasis and T-cell immunotherapy. He completed his postdoctoral training and subsequently served as a researcher at The University of Texas MD Anderson Cancer Center. He also served as a pathologist and Minjiang Scholar Professor at Fujian Medical University previously.

Lieping Chen, MD, PhD​

Co-founder, Scientific advisor

Dr. Chen is a pioneer in cancer immunotherapy. His research focuses on fundamental T-cell biology and the translation of scientific discoveries into clinical therapies, with a primary emphasis on cancer immunotherapy. He discovered PD-L1 and established its role in tumor immune evasion, laying the foundation for anti-PD-1/PD-L1 therapies that have transformed cancer treatment worldwide. Among his other numerous discoveries, B7-H3 has emerged as a promising universal therapeutic target for solid tumors. 

Dr. Chen is United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine at Yale University. He held faculty positions at the Mayo Clinic, Johns Hopkins University, and scientist positions in the Bristol-Myers Squibb Co. before joining Yale University. Dr. Chen is a member of the National Academy of Sciences, the National Academy of Medicine, and a Fellow of the American Association for Cancer Research.